Literature DB >> 73490

Inhibitory effect of tumor-bearing state on the generation of in vivo protective immune T cells in a syngeneic murine tumor system.

H Fujiwara, T Hamaoka, Y Nishino, M Kitagawa.   

Abstract

Tumor-specific immunity mediated by thymus-derived lymphocytes (T cells) was established in C3H/He mice against syngeneic X5563 plasmacytoma. Splenic T cells from mice, which exhibited resistance to tumor challenge, revealed a potent in vivo tumor-neutralizing activity as well as in vitro cytotoxicity. In contrast, spleen cells from mice 7 days after tumor cell inoculation (7-day tumor-bearing mice) exhibited no protective activity when assayed by in vivo tumor-neutralization test, whereas these cells exhibited almost comparable in vitro cytotoxic activity to that from the tumor-resistant mice. Any suppressor cell activity was not detected in 7-day tumor-bearing animals. While a slight in vivo protective activity was observed in the spleen cells from 14-day tumor-bearing mice, this activity was still significantly weaker than that of spleen cells from mice similarly inoculated with tumor 14 days before but whose tumor had been removed 7 days before the assay. The development of in vivo protective immunity in tumor-resected mice was suppressed by intravenous inoculation with 7000 R X-irradiated tumor cells. These results indicate that in vitro reactivity of immune T lymphocyte population is not always correlated with in vivo protective immunity, but there is a substantial decrease in in vivo immune capability of T cells from tumor-bearing animals, and that this suppression may be ascribed to the presence of a large amount of tumor-associated transplantation antigens rather than to suppressor cell activity.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 73490

Source DB:  PubMed          Journal:  Gan        ISSN: 0016-450X


  6 in total

1.  Progression mechanisms in colon cancer: soluble interleukin-2 (IL-2) receptor, IL-2 plus anti-CD3 proliferative response and tumour stage correlations.

Authors:  A M Berghella; P Pellegrini; D Piancatelli; D Maccarone; T Del Beato; D Giubilei; A Pomidori; D Adorno; C U Casciani
Journal:  Cancer Immunol Immunother       Date:  1994-03       Impact factor: 6.968

2.  Regulatory functions of hapten-reactive helper and suppressor T lymphocytes. III. Amplification of a generation of tumor-specific killer T-lymphocyte activities by suppressor T-cell-depleted hapten-reactive T lymphocytes.

Authors:  T Hamaoka; H Fujiwara; K Teshima; H Aoki; H Yamamoto; M Kitagawa
Journal:  J Exp Med       Date:  1979-01-01       Impact factor: 14.307

3.  Suppression of anti-tumor CD4+ T cell responsiveness in the tumor-bearing state and its recovery in in vitro culture free of tumor burden.

Authors:  T Nagata; J P Zou; N Yamamoto; S Ono; H Fujiwara; T Hamaoka
Journal:  Jpn J Cancer Res       Date:  1993-11

4.  Selective suppression of the generation of anti-tumor L3T4+ but not of Lyt-2+ T cell-mediated immunity in the tumor-bearing state.

Authors:  H Sano; S Sato; J Shima; T Tada; H Fujiwara; T Hamaoka
Journal:  Jpn J Cancer Res       Date:  1988-07

5.  Transforming growth factor-beta (TGF-beta)-mediated immunosuppression in the tumor-bearing state: enhanced production of TGF-beta and a progressive increase in TGF-beta susceptibility of anti-tumor CD4+ T cell function.

Authors:  X F Li; H Takiuchi; J P Zou; T Katagiri; N Yamamoto; T Nagata; S Ono; H Fujiwara; T Hamaoka
Journal:  Jpn J Cancer Res       Date:  1993-03

6.  Do structural changes of T cell receptor complex occur in tumor-bearing state?

Authors:  S Noda; T Nagata-Narumiya; A Kosugi; S Narumiya; C Ra; H Fujiwara; T Hamaoka
Journal:  Jpn J Cancer Res       Date:  1995-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.